-
CGOG 2026 Day 5 Finale | Gastric and Esophageal Cancer Forum Highlights Emerging Frontiers
The 16th Peking University Gastrointestinal Oncology Forum and the 2026 Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) were successfully held in Beijing from June 9 to 13, 2026.
-
Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction
At a recent international academic conference, Professor Walter Weber from University Hospital Basel, Switzerland, detailed the results of the international randomized Phase III PREPEC trial (OPBC-02). The study aimed to compare the impact of two implant placement strategies—Prepectoral versus traditional Subpectoral—on the quality of life and safety of patients undergoing implant-based breast reconstruction (IBBR) following…
-
Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation
The treatment of Chronic Myeloid Leukemia (CML) has entered the era of Tyrosine Kinase Inhibitors (TKIs), but the choice of treatment for patients after the failure of first-line therapy remains a focus of clinical attention. Olverembatinib (HQP1351), as the first third-generation TKI independently developed in China, has previously demonstrated excellent efficacy in populations carrying the…
-
EHA Highlights | Professor Zhang Xian: Largest-Ever Cohort of 171 Patients Reinforces the Potential of NS7 CAR-T in Tackling Relapsed/Refractory T-ALL/LBL
Relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) carries an extremely poor prognosis, with long-term survival rates of only 10%–20%. The advent of NS7 CAR-T, a novel naturally selected CD7-directed CAR-T therapy that requires no additional genetic modification, has brought a transformative breakthrough to the treatment of these diseases.
-
EHA Echoes | Prof. Wenming Chen: Advancing Plasma Cell Disease Treatment Through Clinical Innovation and Translational Research with Aponermin-Based Combination Therapies
At the 2026 Congress of the European Hematology Association (EHA), innovative research from Chinese investigators in the field of multiple myeloma attracted significant attention. The team led by Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, presented a series of studies evaluating aponermin (Aponermin)-based combination therapies for multiple myeloma, plasmacytoma, and plasma cell…
-
EHA Echoes | Prof. Liang Wang: CD19/CD22 Dual-Target CAR-T Plus Maintenance Therapy Breaks Through the Long-Term Survival Bottleneck in R/R LBCL
At the 2026 Congress of the European Hematology Association (EHA), Prof. Liang Wang from Beijing Tongren Hospital, Capital Medical University, delivered an oral presentation unveiling the latest follow-up results of CAR2219, a CD19/CD22 dual-target CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study reported an impressive 12-month progression-free survival (PFS)…
-
EHA Echoes from Stockholm | Professor Bing Han: Phase III ESLIM-02 Trial Meets Primary Endpoint, Sovleplenib Poised to Reshape the Treatment Landscape of Warm Autoimmune Hemolytic Anemia
Patients with warm autoimmune hemolytic anemia (wAIHA) have long faced a significant lack of effective second-line treatment options, often becoming trapped in a cycle of corticosteroid dependence and recurrent disease relapse. At the 2026 European Hematology Association (EHA) Congress, Professor Bing Han of Peking Union Medical College Hospital presented the pivotal results of the Phase…
-
EHA Echoes from Stockholm | Professor Jiarui Zhou and Dr. Jingyu Wang: Outcomes of CAR-T Followed by Allogeneic HSCT in Adult TCF3::PBX1-Positive Acute Lymphoblastic Leukemia
The 2026 European Hematology Association (EHA) Congress, held from June 11–14 in Stockholm, Sweden, brought together leading experts from around the world to showcase the latest advances in basic, translational, and clinical hematology.
Connecting Medical Expertise through Media